Prothena Reports Fourth Quarter and Full Year 2023 Financial Results, and Provides Financial Guidance and Business Highlights
In addition, the Company provided 2024 financial guidance and business highlights.
- In addition, the Company provided 2024 financial guidance and business highlights.
- “2023 was a year of strong progress for Prothena as we advanced our protein dysregulation portfolio and moved closer to becoming a fully integrated commercial company.
- Total revenue for the fourth quarter and full year of 2023 included BMS collaboration revenue of $0.3 million and $91.3 million, respectively.
- As of December 31, 2023, Prothena had $621.0 million in cash, cash equivalents and restricted cash, and no debt.